The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Plasma GPC3 and its association with tumor GPC3 expression and clinical outcomes in advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.
 
Dong Jun Shin
No Relationships to Disclose
 
Sohyun Hwang
No Relationships to Disclose
 
Beodeul Kang
No Relationships to Disclose
 
Won Suk Lee
No Relationships to Disclose
 
So Jung Kong
No Relationships to Disclose
 
Hannah Yang
No Relationships to Disclose
 
Haeyoun Kang
No Relationships to Disclose
 
Sung Lee
No Relationships to Disclose
 
Jung Sun Kim
No Relationships to Disclose
 
Jinhyung Heo
No Relationships to Disclose
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
Speakers' Bureau - Bayer
 
Jingwen Shi
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Yongchun Tong
Employment - BeiGene
 
Gwangil Kim
No Relationships to Disclose
 
Chan Kim
No Relationships to Disclose
 
Hong Jae Chon
Consulting or Advisory Role - Aptamer Sciences Inc; AstraZeneca; Bayer; BeiGene; BMS; Eisai; MSD; Ono Pharmaceutical; Roche; Sanofi; SERVIER
Speakers' Bureau - AstraZeneca; Bayer; BMS; Dong-A ST; Eisai; Roche; Sanofi; SERVIER
Research Funding - BeiGene (Inst); Boryung (Inst); Dong-A ST (Inst); Hanmi (Inst); inno-n (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Medivir (Inst)